Natural products are made by nature through interacting with biosynthetic enzymes. Natural products also exert their effect as drugs by interaction with proteins. Does the recognition of the natural product by biosynthetic enzymes translate to recognition of the therapeutic target? Molecular modelling of flavonoid biosynthetic enzymes and protein kinases with a series of natural product kinase inhibitors led to the development of the concept of Protein Fold Topology (PFT). PFT describes cavity recognition points unrelated to protein fold similarity. The topology or spatial properties are preserved even though there is deformation of the protein elemen ts that participate in the protein-ligand interactions. We observe helices or -sheets as equivalent in providing the invariant topology for protein-ligand interaction. In this review,
Introduction
Nature has proven to be one of the richest sources of therapeutically useful compounds.
Natural products are produced biosynthetically within organisms, in order to aid their survival. These compounds may function within the organism itself or externally. In the latter case, natural products act either as toxins to inhibit a critical pathway within other organisms, or as pheromones in order to attract or repel or other organisms. This highlight provides a perspective of the significant impact natural products have made on the discovery of therapeutic agents by linking interactions of these compounds with the biosynthetic protein on the one hand, and the target/receptor protein on the other. The intriguing question is thus whether such interactions during biosynthesis can be leveraged as a drug discovery tool. Drug discovery requires the identification of molecules that interact with biological systems. The relevant biological structure space comprises the protein binding sites for potential ligands. Ligands are recognized by proteins in specific binding pockets, complementary in shape and physicochemical properties to the accommodated small molecule. If two binding pockets of different proteins share a common motif, it is likely that ligands or ligand fragments that bind within one binding pocket will also be recognized in the respective part of the other binding pocket. Ligand binding sites in disease targets serve the purpose of binding the endogenous ligand. Firstly, modulation of a disease target by a drug compound is more likely, if the drug and the endogenous ligand share common interactions with the target protein. These common interactions would be a consequence of a shared complementarity between biological and chemical structure space between the endogenous ligand and the drug. Secondly, since natural products are of biosynthetic origin, they possess an imprint of the biological structure space in the biosynthetic enzyme. The endogenous ligand therefore carries information about two different binding sites on proteins, the biosynthetic enzyme and the target protein.
The drug discovery task is to find compounds that are complementary to this structure space by correlating biological structure space with chemical structure space (Figure 1 ). However, the chemical structure space as produced in synthetic libraries often fails to overlap sufficiently with biological structure space. KGaA.
If we can unravel the common motif shared by the binding pockets of biosynthetic enzymes and the binding pockets of therapeutic targets, then we would not only understand the reason for the higher relevance of natural products in the development of therapeutics, but also obtain a tool improving rationale probing of biological space to obtain novel therapeutically useful compounds. This highlight will examine the question if the recognition of a natural product by biosynthetic enzymes translates to recognition by the therapeutic target and whether such recognition would aid drug discovery.
Natural product approaches to drug discovery
The quest for new therapeutics has been approached by varying methods over time. Natural products represent one of the most enduring approaches to this goal. Historically, natural products from plants have been the basis for traditional medicine systems for thousands of years and according to the World Health Organisation (WHO) are still relied upon for primary health care by approximately 80% of the residents of developing countries in the world. Several reviews have been published which discuss this point. An example of the dominant role of natural products can be seen in the last 25 years where in the cancer therapeutic area, 77.8% of approved drugs are either natural products, based on natural products, or mimicks of natural products. As of 2001 the number of globally used drugs derived from plants was estimated as 122 with 80% of these drugs having the same or related use as the plants from which they were derived. These figures indicate that only 20% of plant derived drugs were discovered independent of medicinal folkloric information.
Today, in the face of increasing pressure to identify new lead compounds, several approaches to drug discovery from natural products are being explored. Screening techniques are widely employed today to discover new leads on the basis of the therapeutic target function. Recent times have seen the emergence of computing techniques to address, at the genomic scale, the target-ligand recognition issue.
The screening approach benefits from combinatorial chemistry made by nature
The most common current approach to drug discovery from natural products is through screening.
In most cases, collections of random samples are gathered and extracts tested for pharmacological properties. In the case of activity, the responsible natural product entity is identified and carried forward for further investigation. With the speed of High Throughput Screening (HTS) outpacing the rate of compound supply, the introduction of combinatorial chemistry some 20 years ago saw focus shift towards combinatorial chemistry with its promise of an abundance of compounds. Although the technology undoubtedly proved itself in its ability to efficiently provide large quantities of compounds for screening, combinatorial chemistry has not delivered the expected wealth of new drugs. Reports that only one de novo combinatorial compounds was approved as drug before 2006 [Newman and Cragg, 2007 , J Nat Prod 70 461_477] reflect this assessment. In the last decade, the question of quality over quantity with respect to combinatorial chemistry has thus become apparent.
However, combinatorial chemistry can, and has been employed to build upon the lessons learned by nature and using nature's own compounds as the basis for library development. There have been several comprehensive reviews of the types of combinatorial libraries which have been inspired by natural products. A review of libraries from natural product-like scaffolds in 2004 encompasses over fifty reported libraries based on carbohydrates, steroids, fatty acid derivatives, polyketides, peptides, terpenoids, flavonoids, alkaloids and other natural products. Aside from natural product libraries based upon combinatorial techniques there are other types of libraries based upon natural products which include pre-fractionated natural product libraries, pure natural product libraries, synthetic and semi-synthetic natural product libraries, focused libraries and natural product derived compound libraries based on diversity-modified natural scaffolds.
Chemical biology has brought new sources of inspiration
Recent times have seen more direct methods of harnessing the qualities of natural products based upon an understanding of the underlying specifics of their biological relevance. "Chemical biology" is a term that encapsulates target family concepts which focus on the ligand binding property of proteins to efficiently address the druggable genome. It is founded on the assumption that similar ligands bind to similar proteins. Two targets can be linked if they share common ligands, or alternatively, if they share common structural characteristics.
Associations among proteins on the basis of ligand chemical structure has allowed the prediction of new targets for known drugs. For instance, some side effects of emetin, a natural product extracted from ipecac root, could be explained by the identification of the α2-adrenegic receptor as an off-target. While being a potent antiprotozoal agent, emetin may produce nausea, hypotension, tachycardia and congestive heart failure. The chemical structure of emetin revealed similarity to α2-adrenegic ligands, and the compound was indeed shown to modulate the α2-adrenegic receptor at 1 μM concentration, consistently with some of the adverse reaction of this drug.
A global analysis of the common ligands of a few hundred therapeutic targets revealed that many bioactive ligands are able to bind proteins assigned to different pharmacological classes. For instance, ligands of aminergic G-protein coupled receptors are often observed to target protein kinases; ligands of protein kinases have in turn been observed to possess unexpected activities on ion channels and phosphodiesterases. Since these targets are not homologuous proteins, they possess three-dimensional structural similarities in their ligand binding areas in the absence of significant sequence identity.
The direct comparison of protein three-dimensional structures has been successfully applied to target identification for natural product starting points. Early studies used the fact that a particular natural product binds to a protein with a particular fold, in order to develop compound libraries based on the natural product scaffold and targeted at other members of the same fold. The discovery of novel and highly selective inhibitors of tyrosine kinases vascular endothelial growth factor receptors 2 and 3 (VEGFR-2,-3), Tie-2 and insulin-like growth factor 1 receptor (IGF1R) was achieved by the selection of nakijiquinones, which are known inhibitors of the human epidermal growth factor receptor tyrosine kinase (Her-2/neu), as a scaffold for a screening library targeted at other receptor tyrosine kinases. The ligand binding properties of a protein are however not systematically encoded in the overall fold, and a single fold may correspond to different protein functions, which themselves are associated to distinctive local structures. In an attempt to focus on the local structural similarity, the Waldmann group defined protein structure similarity clusters (PSSC). The ligand-sensing core is made of the secondary structure elements forming the ligand-binding domain, and thus consists in a subdomain of the overall fold. Compound libraries were developed to address a particular PSSC based on knowledge of natural product inhibitors of members of the cluster Proteins that share structural similarity despite low sequence identity are considered the most interesting cases. In a practical application this approach has afforded new inhibitors of members of the same PSSC; CDc25A phosphatase, acetylcholinesterase, and 11β-hydroxysteroid dehydrogenase type 1 and type 2. Inhibitors were contained within a 147-membered compound library based upon the natural product inhibitor of Cdc25A, dysidiolide, and the hypothesized importance of the γ-hydroxybutenolide group for the natural product's phosphatase inhibiting activity the sentence has to be rewritten as the meaning is unclear Though the enzymes screened in this PSSC are defined as having different folds according to SCOP (Structural Classification of Proteins Database), their active sites are nevertheless located in subdomains of common topology.
Recent considerations about the protein 3D similarity suggested that the conservation of structural fragments between proteins may be a signature of a common function, even in the absence of global sequence or fold similarity. The Honig group has thus deophanised a protein of unknown function from Thermatoga maritima. A scan of the Protein Databank identified structural neighbours defined by containing at least three aligned secondary structure elements with the query protein, thereby suggesting potential ligands. Boosted by the special interest of pharmaceutical companies to predict adverse drug reaction, the prediction of a ligand's target on the basis of protein local structure has become an active field of research. Because large scale studies demonstrated that two proteins can bind the same ligand even though they don't share sequence or fold similarity, methods and programs have been developed to address the protein local similarity issue independently of the sequence, the overall fold and the subdomain topology of proteins As a proof of concept, the Klebe group could explain the crossreactivity of cyclooxygenase type-2 inhibitors with carbonic anhydrase. A common three-dimensional organisation of the pharmacophoric features exposed at the protein surface was observed in the two enzymes, although there was not a perfect match of shape and physicochemical properties of the enzyme active sites. Up to now, only two prospective studies successfully detected common binding sites among proteins unrelated in sequence and/or function. In both cases, a systematic search across the Protein Data Bank using the binding site of a given drug target as the query allowed the identification of a new off-target for the drug. In 2009, the Bourne group evidenced a relationship between the NADbinding Rossmann fold of M.tuberculosis enoyl-acyl carrier protein reductase (InhA) and the SAM-binding domain of catechol-O-méthyltransferase (COMT), through similarities between their co-factor binding sites. Both theoretical proteinligand docking and experimental antibacterial assays supported the computational predictions that synthetic COMT inhibitors, which are indicated for Parkinson's disease, also inhibit M.tuberculosis InhA. The next year, the Rognan group screened a library of 6,412 druggable protein-ligand binding sites thereby identifying an off-target for natural products used as inhibitor of protein kinases. Local structural similarity was observed between the ATP-binding sites of protooncogene Pim-1 kinase and synapsin I, a protein which regulates the neurotransmitter release in the synapse (Fig. 2) . Binding and functional assays confirmed the predictions; The generic kinase inhibitor staurosporine was shown to bind synapsin I and to induce a functional response with submicromolar potency; The Pim-1 kinase selective inhibitor quercetagetin was as efficient yet twice more potent than staurosporine. No binding to synapsin I could be detected for a protein kinase A inhibitor or a protein kinase Chk1 inhibitor.
Detection of binding sites
In practice, binding site comparison algorithms involve three interrelated components; firstly the simplified representation of the site with various biochemical properties, secondly an algorithm to detect and superimpose common motifs, and thirdly a method to score the resulting match. The quantification of local similarity between protein threedimensional structures is generally thought of as a structural alignment problem; equivalences between two binding sites are established by optimising structure superposition. In brief, the methods used in this context so far include: -ASSAM (Artymiuk et al., 1994) reduces residue side chains to pseudo atoms and uses subgraph isomorphism to find common patterns between template and target. -Cavbase (Schmitt et al., 2002) In the two examples described above (InhA/COMT and Pim-1 kinase/synapsin I), the protein representation was reduced to Cα atoms, which were defined with their 3D coordinates as well as the physico-chemical and geometrical properties of the corresponding residues.
Other methods describe the protein as the collection of the numerous pharmacophoric features at the binding site surface, thus including all hydrogen bond donors and acceptors, the positively and negatively charged groups, as well as the hydrophobic and aromatic groups). The pharmacophore-based approach has successfully identified targets for natural products. As an example, arborinine extracted from the medicinal plant Ruta graveolens was compared to 2208 structure-based and ligand-based pharmacophores, and found to match the pharmacophore derived from acetylcholinesterase (Fig. 2) In principle, the ligand-binding preference of a query protein can be deduced from knowledge about the ligand binding preference to a target proteins provided a significant match is established between the protein-based pharmacophores of the query and the target proteins. Such an application has not yet been published.
Concepts around biosynthesis and biology space
The target-orientated approaches described involve using a specific natural product interaction with a target protein to guide identification of targets related by a specified degree of structural similarity. However, the natural product-target interaction is not the only interaction which can be exploited for target identification. The interactions made by natural products with their biosynthetic machinery presents another avenue for target identification.
Biosynthetic world
Natural products, or secondary metabolites, may be defined as naturally produced substances which do not play an explicit role in the internal economy of the organism that produces them. The reasons for their production is not entirely clear. It has been argued that organisms have evolved this ability to produce natural products because the functions of such compounds evidently serve the organism by improving its survival fitness. These roles include defending many species of plants, animals and micro-organisms against predators, pathogens and competitors A particular natural product may serve its producing organism by acting as a toxin, repellent or attractant. The natural product exerts its effect through protein binding. From this we can conclude that nature has produced compounds which have the inbuilt capacity to interact with biology space. Despite the huge number of natural products being produced by organisms, for the vast majority, little is known about their actual role in nature. These compounds are manufactured in pathways consisting of an assembly line of biosynthetic enzymes, and thus have an imprint of their interaction with biology space from their very origin. Intriguingly, while natural products are not produced by nature to medicate humans, they do contain properties that make them favourable drug candidates. Natural products, having evolved in nature to interact with the biology space of proteins, have already accomplished what so many synthetic approaches aim to achieve. The reason that natural products are biologically validated starting points for drug design and hold the key to optimising the occupation of biology space is specifically due to their biosynthetic origin, the imprint of biology space and the common recognition elements within the limited protein structural arrangements.
Protein Folds
Within the protein world, there are a limited number of structural arrangements available and this knowledge has been leveraged. The majority of protein families belong to approximately 1000 common folds, describing the relative orientation of a particular set of secondary structure elements in three-dimensional space. The finite number of folds provides a simplification of biology space presented by proteins. The question of interest is whether the interaction of natural products coded into their scaffold transfers into their interactions with a human target in a rational way.
The Protein Fold Topology (PFT) concept
As mentioned previously, examples exist of the application of the chemical biology approach to identify a new protein target for a natural product related by structural similarity. Our own efforts have been aimed at identifying what relationship is shared between a target and a biosynthetic enzyme of a natural product. Comparison made at the scale of local secondary structures revealed unexpected common organisation of the secondary structures forming the natural product binding sites. This structural similarity was defined as Protein Fold Topology (PFT).
The first PFT to be identified was the Flavonoid/kinase PFT. This investigation around flavonoids ( fig. 3 ) was motivated by three main reasons: first the flavonoid biosynthetic pathway is well characterised, then flavonoids are known to inhibit a broad range of kinases, and last structures are available within the Protein Data Bank for both biosynthetic enzymes and therapeutic targets. The phosphoinositide 3-kinase was compared by eye to three biosynthetic enzymes (chalcone synthase, chalcone isomerase and anthocyanidin synthase) to identify the common secondary structure elements within a sphere of approximatively 15Å centered on the protein-bound ligand. The overlay of the PFT shared between anthocyanidin synthase and the phosphoinositide 3-kinase is illustrated in Fig. 4 . Corresponding alignments and RMS deviations are given in Table 1 . The quality of the RMS deviations for individual segments reflects the similarity in the positioning of secondary structure elements. By contrast with the ligandsensing core of the PSSC approach, the PFT does not represent the fold of the active site domain, but consists in a limited number of secondary structure elements which form the active site and whose spatial arrangement is common to proteins which are unrelated by their sequence or their domain fold, but are related by the binding of common ligands, here flavonoids.
The PFT was also detected in the active sites of chalcone synthase and chalcone isomerase, with little variations in the number and the boundaries of considered secondary elements. Interestingly, the hydrogen binding pattern between quercetin and phosphoinositide 3-kinase is partly reproduced in the complex between quercetin and anthocyanidin synthase. As shown in Fig. 4 , although the position of quercetin with respect to the PFT differs in the two enzymes, there is a good match between hydrogen bond interactions of the two enzymes with quercetin in select instances. The relative position of the key hydrogen bond donors and acceptors in chalcone synthase and chalcone isomerase, however, do not agree with those observed in phosphoinositide 3-kinase and anthocyanidin synthase. This is consistent with recently suggested multiplicity of flavonoid binding modes
The PFT study has demonstrated that the relationship between a natural product's biosynthetic enzyme and therapeutic target is not simple. The similarity is not obvious and the subtleties of the relationship still need to be understood. In its simplest form, PFT uses the existence of secondary structure elements that make up the ligand binding site. Since ligands may interact with different main chain or side chain residues in the binding site when comparing template and target proteins, detailed atomic information as well as physicochemical properties are ignored in the first instance. Obviously, the position and orientation of the secondary structure elements has implications for the required shape complementarity (see Cavbase approach), but the PFT concept allows the substitution of one type of secondary structure element (helix, strand, etc) with another.
/// What is maybe missing here : -Is the PFT a signature of flavonoid binding? In other words, it is a common motifs, also found in proteins which do not bind flavonoid at all ? -Do other known flavonoid targets contain the identified PFT (eg. the estrogen receptor)? People can rightly argue that geometric similarity may simply reflect structural and energetic constraints associated with the packing of secondary structure elements /// In practice, the PFT approach lacks an automated identification tool, thus only a mature limited number of PFT relationships have been established to date. On this aspect, more research is necessary. A possible clue relies on the use of protein 3D-alignment methods. There are a number of algorithms available which perform different aspects of similarity searching; none of them, however, perfectly suits PFT identification. Current computational methodologies can be classified into two categories. (i) Algorithms designed to perform threedimensional superposition of a target and a template protein require reasonable structural homology globally or in a sequential section of the protein(s). While intrinsic restrictions caused by superposition of atomic coordinates by least squares methods are overcome by secondary structure matching [LIT] or alignment of gravitational axes [LIT] , neither of the latter lends itself for the PFT problem. (ii) Algorithms exclusively comparing ligand binding sites address ligand-protein interactions at the level of atoms or residue side chains. The distinguishing feature of PFT, the occurrence of similar secondary structure positioning, is not considered. PFT similarity does not require the same secondary structures to be compared, so that algorithms which effectively increase the structural similarity at the fold level of matched proteins will not include proteins that have similarity on the PFT level. Next, while proteins which share PFT may have similar binding sites, it is unknown if all proteins with similar binding sites will share similarity at the PFT level. For this reason, binding site comparison does not provide an answer for automated PFT searches. Recent discussions of the evolution of proteins have suggested a continuity of the protein structural space, whereby essentially all protein structures can been linked from an arbitrary starting structure using a transitive set of a few structurally related neighbours. A common set of superimposed secondary structure elements is the hallmark of two structural neighbours. The fine-grained analysis of the 3D-alignment of structural neighbours reveals that a single helix can replace a β-strand (and vice-versa), which aligns parallel to the principal axis of the helix.
This view of protein evolution support the existence of PFT for the conservation of function between proteins unrelated by the overall fold. . Fig. 4 The flavonoid/kinase Protein Fold Topology (PFT) overlay. The secondary structure elements shared between anthocyanidin synthase (magenta ribbon at the left side) and phosphoinositide 3-kinase kinase (green ribbon, at the right side). The top pictures replace the PFT in the protein overall fold (grey tubes), the bottom pictures show a detailed view of the active sites, including the co-crystal ligand (capped stick representation, with CPK color coding) and the amino acids interacting with the ligand via hydrogen bond (space filled representation, protein color coding): Lys213, Glu306 and Asp234 in anthocyanidin synthase and Val882 and Asp964 in phosphoinositide 3-kinase kinase. resulting in kinase recognition is not reflected in other biosynthetic enzymes. We expect that different biosynthetic enzymes will generate different interactions giving rise to additonal PFTs. Therefore, to establish the universality of PFT, we need to 5 identify other pairs of biosynthetic enzyme/therapeutic target with identical binding modes. This would establish that different biosynthetic enzymes can serve as starting point for drug design,.
Biosynthetic interactions reflected in target recognition
In conclusion, we define the concept of "biosynthetic imprint" 10 as the molecular recognition between substrate and biosynthetic enzyme and "natural product binding motif" as the molecular recognition between ligand and therapeutic target. A PFT ESTHER _ PLEASE CONSIDER ABOVE 15
Implications for drug design
In the case of flavonoid metabolic enzymes/kinases, natural products of the flavonoid biosynthetic pathway represent starting points for drug design against protein kinases. The 20 ability for flavonoids to function not only as kinase inhibitors, but as a potential kinase drug is demonstrated through the case of flavopiridol. Flavopiridol (Fig. 9) is the first potent inhibitor of cyclin dependent kinases and is currently in Phase III clinical trials } } fitoterapia 81 (2) We have recently used bioaffinity mass spectrometry to screen natural product extracts for ligands that bind to bovine carbonic anhydrase II. We identified the coumarin (6) as a ligand for the enzyme. In subsequent work we determined 35 that 6-(1S-hydroxy-3-methyl-butyl)-7-methoxy-2H-chromen-2-one (6) inhibited a range of human and murine carboninc anhydrases with greatest affinity against human CA II (K I 59 nM) and CA I (K I 80 nM). A crystal structure obtained by soaking 6 with human CA II showed that the ring open 40 cinnamic acid 7 was present in the active site of human CA II. Fig. 6 The structure of 6-(1S-hydroxy-3-methyl-butyl)-7-methoxy-2H-chromen-2-one (6) and the ring open form (7) observed in the crystal structure with hCA II (5).
45
As the biosynthetic enzymes of coumarin biosynthesis are known, we compared the binding mode observed in the human CA II ligand-bound crystal structure with docking of 6 and 7 into the biosynthetic enzymes. RESULT?
50
The identification of PFT provides another avenue for application of the chemical biology approach in drug discovery. Essentially, the automated comparison of PDB structures can serve three different aims (Fig. 10) . Given a 55 new therapeutic target, a similarity search could identify a biosynthetic enzyme, and the corresponding natural product would provide a starting point for drug design against the target. Similarly, a new natural product and its associated biosynthetic enzyme could be used to conduct a search for a 60 potential target.
Finally, PFT could be used with an established natural product-target relationship to direct a search for new targets. All three approaches require a substantial number of X-ray structures of biosynthetic enzymes. 1,048 genes (3.5% of the genome) produce all proteins that are targets of current drugs. All current drugs with a known mode-of-action act through 324 distinct molecular drug targets. Of these, 266 are human-genome-derived proteins, and the remainder are bacterial, viral, fungal or other pathogenic organism targets. Small-molecule drugs modulate 248 proteins, of which 207 are targets encoded by the human genome. Oral small-molecule drugs target 227 molecular targets, of which 186 are human targets. In order to identify the familial relation-ships between all drug targets, the analysis domains, using the SCOP19 and PFAM20 databases showed that approximately 130 15 'privileged druggable domains' cover all current drug targets. This number is in stark contrast to the projected number of protein families and folds (10,000 folds21 and more than 16,000 families22). One striking feature was that of the 361 new molecular entities (NMEs) approved by the FDA between 1989 and 2000, 76% targeted a precedented drugged domain and only 6% targeted a previously undrugged domain; the remainder have either unknown targets (4%) or are believed not to have distinct molecular targets underlying their action (17%). The rate of target innovation is surprisingly constant over the past 20 years, with an average rate of first-against-target A growing number of X-ray structures for biosynthetic enzymes 25 Since crystal structures of biosynthetic enzymes form the basis of the suggested PFT methodlogy, we appraised the their availability up to early 2006 is presented. An advanced search of the PDB was performed using the key words biosynthesis and tailoring. These particular key words were successful in 30 returning previously identified biosynthetic enzyme crystal structures. A full text search scope was selected and the search returned 2566 structures for the first keyword and 6 for the second. The search also retrieved some entries such as enzymes involved in "protein biosynthesis" which were Fig. 11 . The X-ray structures 20 available within this pathway and the natural products biosynthesised are given in Table 7 . While the number of elucidated structures of biosynthetic enzymes is growing with increasing speed, there is still enormous potential for structure determination especially for enzymes not involved in major pathways and for those which 5 play a role in the final stages of biosynthesis for interesting natural products. Given the correlation found between the target and biosynthetic enzymes of natural products, value should be placed on structure determination of biosynthetic enzymes to allow for further exploration of this new avenue to 10 drug design. 
Conclusions
Synthesis in the biosphere, per se, does not endow a natural product with the property of modulating the function of proteins of therapetic potential. The fact that natural 5 products have already experienced an interaction with a protein also does not, a priori, impart any ability to sense a protein surfaces at sites that modulate therapeutic targets.
In the case where the intended target protein of a natural 10 product has a human homologue which is involved in disease, it is clear that the natural product can affect the human target. However, this does not explain the occurrence of high numbers of natural products that interact with therapeutic targets.
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Using the new methodology of PFT to describe the imprint of the biological interactions during biosynthesis it is suggested that this imprint does indeed correspond to interactions with therapeutic targets. 20 An important reason may be the conservation of We conclude from PFT that, as all secondary metabolites 25 are engineered by interacting with enzymes through biosynthetic pathways, all such compounds represent potential starting points for drug design.
(ESTHER ?) 30 We have reviewed the possibility to use the biological imprint during biosynthesis (PFT) as a drug discovery tool with respect of identifying molecular targets rather than relying on screening methods.
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Natural products provide a chemical diversity set that contains compounds that are complementary to biological structure space (Fig. 1) . The Protein Fold Topology correlations discovered between a 40 natural product's biosynthetic enzyme and therapeutic target explains why so many natural products have become therapeutic agents. PFT defines a natural product's ability to recognise biology space and represents a potential tool for drug design.
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Expand conclusion section -reiterate main points and utility of PFT and compare to alternative approach of PSSC (and others). Is your method limited to the druggable genome or 50 is there potential to use it to identify metabolites that might be used to interfere with proteinprotein interactions? What are the benefits/advantages and limitations of your method. 
